# Narasin.
**AGENCY:**
Food and Drug Administration, HHS.
**ACTION:**
Final rule.
**SUMMARY:**
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during March 2012. FDA is also informing the public of the availability of summaries of the basis of approval and of environmental review documents, where applicable.
**DATES:**
This rule is effective May 17, 2012.
**FOR FURTHER INFORMATION CONTACT:**
George K. Haibel, Center for Veterinary Medicine (HFV-6), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9019, email: *[email protected].*
**SUPPLEMENTARY INFORMATION:**
FDA's Center for Veterinary Medicine (CVM) is adopting use of a monthly *Federal Register* document to codify approval actions for NADAs and abbreviated ANADAs. CVM will no longer publish a separate rule for each action. This approach will allow a more efficient use of available resources.
In this document, FDA is amending the animal drug regulations to reflect the original and supplemental approval actions during March 2012, as listed in table 1 of this document. FDA is also informing the public of the availability of environmental review documents required under the National Environmental Policy Act (NEPA), where applicable. For actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA) may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.
| NADA/ANADA | Sponsor | New animal drug product name | Action | 21 CFR Section | FOIA summary | NEPA review |
| --- | --- | --- | --- | --- | --- | --- |
| 118-980 | Elanco Animal Health, A Division of Eli Lilly & Co., Lilly Corporate Center, Indianapolis, IN 46285 | MONTEBAN (narasin) Type A medicated article | Supplement increasing the upper dose limit for narasin in broiler feed | 558.363 | Yes | Environmental assessment (EA)/Finding of no significant impact (FONSI). |
| 111-636 | Pharmacia & Upjohn Co., a Division of Pfizer, Inc., 235 East 42d St., New York, NY 10017 | LINCOMIX (lincomycin hydrochloride) Soluble Powder | Supplement adding an indication for control of American foulbrood in honey bees | 520.1263c | Yes | Categorically excluded (CE). |
| 200-421 | Hospira, Inc., 275 N. Field Dr., Lake Forest, IL 60045 | Ceftiofur for Injection (ceftiofur sodium) Sterile Powder | Original approval of generic copy of NADA 140-338 | 522.313c | Yes | CE. |
| 200-455 | Cross Vetpharm Group, Ltd., Broomhill Rd., Tallaght, Dublin 24, Ireland | TYLOMED-WS (tylosin tartrate) Soluble Powder | Supplement adding an indication for control of porcine proliferative enteropathies | 520.2640 | Yes | CE. |
| 200-473 | Huvepharma AD, 33 James Boucher Blvd., Sophia 1407, Bulgaria | TYLOVET Soluble (tylosin tartrate) | Supplement adding an indication for control of porcine proliferative enteropathies | 520.2640 | Yes | CE. |
This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.
**List of Subjects**
Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.
Animal drugs.
Animal drugs, Animal feeds.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 520, 522, and 558 are amended as follows:
**21 CFR Part 510**
**PART 510—NEW ANIMAL DRUGS**
1. The authority citation for 21 CFR part 510 continues to read as follows:
**Authority:**
21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.
**21 CFR Part 510**
2. In § 510.600, in the table in paragraph (c)(1), alphabetically add an entry for “Hospira, Inc.”; and in the table in paragraph (c)(2), numerically add an entry for “000409” to read as follows:
§ 510.600
(c) * * *
(1) * * *
| Firm name and address | Drug labeler code |
| --- | --- |
| | |
| * * * * * | |
| Hospira, Inc., 275 North Field Dr., Lake Forest, IL 60045 | 000409 |
| | |
| * * * * * | |
(2) * * *
| Drug labeler | Firm name and address |
| --- | --- |
| | |
| * * * * * | |
| 000409 | Hospira Inc., 275 North Field Dr., Lake Forest, IL 60045. |
| | |
| * * * * * | |
**21 CFR Part 520**
**PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS**
3. The authority citation for 21 CFR part 520 continues to read as follows:
**Authority:**
21 U.S.C. 360b.
**21 CFR Part 520**
4. In § 520.1263c, revise paragraph (b) and add paragraph (d)(3) to read as follows:
§ 520.1263c
(b) *Sponsors.* See sponsor numbers in § 510.600(c) of this chapter for use as in paragraph (d) of this section.
(1) No. 000009 for use as in paragraph (d) of this section.
(2) Nos. 046573, 054925, 061623, and 076475 for use as in paragraphs (d)(1) and (d)(2) of this section.
(d) * * *
(3) *Honey bees* —(i) *Amount.* Mix 100 milligrams lincomycin with 20 grams confectioners'/powdered sugar and dust over the top bars of the brood chamber once weekly for 3 weeks.
(ii) *Indications for use.* For the control of American foulbrood ( *Paenibacillus larvae* ).
(iii) *Limitations.* The drug should be fed early in the spring or late in the fall and consumed by the bees before the main honey flow begins to avoid contamination of production honey. Complete treatments at least 4 weeks before main honey flow.
**21 CFR Part 520**
5. In § 520.2640, revise paragraph (b) introductory text to read as follows:
§ 520.2640
(b) *Sponsors.* See Nos. 000986, 016592, and 061623 in § 510.600(c) of this chapter.
**21 CFR Part 522**
**PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS**
6. The authority citation for 21 CFR part 522 continues to read as follows:
**Authority:**
21 U.S.C. 360b.
**21 CFR Part 522**
7. In § 522.313c, revise paragraphs (b), (e)(2)(ii), (e)(3)(ii), (e)(4)(ii), and (e)(8)(i) to read as follows:
§ 522.313c
(b) *Sponsors.* See Nos. 000009, 000409, and 068330 in § 510.600(c) of this chapter.
(e) * * *
(2) * * *
(ii) *Indications for use.* For treatment of bovine respiratory disease (shipping fever, pneumonia) associated with *Mannheimia haemolytica, Pasteurella multocida,* and *Histophilus somni.* Also, for the treatment of acute bovine interdigital necrobacillosis (foot rot, pododermatitis) associated with *Fusobacterium necrophorum* and *Bacteroides melaninogenicus.*
(3) * * *
(ii) *Indications for use.* For treatment of sheep respiratory disease (sheep pneumonia) associated with *Mannheimia haemolytica* and *Pasteurella multocida.*
(4) * * *
(ii) *Indications for use.* For treatment of caprine respiratory disease (goat pneumonia) associated with *Mannheimia haemolytica* and *Pasteurella multocida.*
(8) * * *
(i) *Amount.* 1.0 mg/lb (2.2 mg/kg) body weight by subcutaneous injection. Treatment should be repeated at 24-hour intervals for 5 to 14 days.
**21 CFR Part 558**
**PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS**
8. The authority citation for 21 CFR part 558 continues to read as follows:
**Authority:**
21 U.S.C. 360b, 371.
**21 CFR Part 558**
9. In § 558.363, revise paragraph (d)(1)(i) introductory text to read as follows:
§ 558.363
(d) * * *
(1) * * *
(i) *Amount per ton.* Narasin, 54 to 90 grams.
Dated: May 7, 2012.
Bernadette Dunham,
Director, Center for Veterinary Medicine.